PubMed Health⌕ Search

Biomedical subjects

I R MacGregor

Publications and source records attributed to I R MacGregor.

49 records · Page 3Linked to original sources
PubMed1985

Characterisation of epitopes on human tissue plasminogen activator recognised by a group of monoclonal antibodies.

Seven mouse monoclonal antibodies have been produced against human melanoma tissue plasminogen activator (t-PA). They were specifically bound to 125I t-PA but not 125I urokinase (u-PA) and inhibited t-PA, but not u-PA, activity in plasminogen-rich 125I fibrin wells. Three of the antibodies directly inhibited the amidolytic activity of t-PA and the two most effective also bound near the active site histidine residue as determined by competition experiments using active site blocking agents. Several antibodies interfered with the fibrin binding properties of t-PA. One antibody neither interacted with the active site nor inhibited fibrin binding but still effectively quenched t-PA activity in fibrin wells suggesting that it masks another region of the molecule necessary for effective biological activity.

Animals↗
PubMed1984

Quantitation by radioimmunoassay of thrombospondin synthesised and secreted by human endothelial cells.

Synthesis and secretion of thrombospondin by cultured human endothelial cells was quantified using a sensitive radioimmunoassay. Two endothelial lines were examined; those from umbilical veins and those from saphenous veins. The foetal line secreted approximately 17 micrograms/10(6) cells of the antigen at 24 hr, whereas the saphenous line secreted five times less in the same period. Intracellular values were similar in both lines. Thrombin and calcium ionophore A23187 were added to umbilical vein endothelial cultures. In contrast to platelets where both agents cause a rapid release reaction, no such thrombospondin release was observed in endothelial cells.

Calcimycin↗
PubMed1984

Metabolism of sodium pentosan polysulphate in man--catabolism of iodinated derivatives.

An iodinated derivative of the heparin analogue SP54 has been prepared and used in conjunction with unlabelled SP54 to study the catabolism and organ distribution of this potential antithrombotic agent in healthy human volunteers. As observed previously with 125I-heparin, we found that the 125I-SP54 was rapidly cleared from the circulation, returning later in a desulphated form. Organ distribution studies with 123I-SP54 suggested that the liver and spleen were major sites of desulphation. Gel filtration and Polybrene binding showed the presence of sulphated macromolecular SP54 and desulphated macromolecular and depolymerised SP54 in post-injection urines. No depolymerised material was present in plasma suggesting depolymerisation occurs in the kidney.

Adult↗
PubMed1984

A comparative study using immunological and biological assay of the haemostatic responses to DDAVP infusion venous occlusion and exercise in normal men.

In a group of six normal male volunteers, infusion of DDAVP, venous occlusion and exercise were shown to increase plasma levels of factor VIII and plasminogen activator, activity and antigen, to different extents and at differing rates. Any mechanisms suggested to explain release of these proteins by various stimuli should account for such differences. All three stimuli could also increase plasma levels of prostacyclin metabolites, although this was only significant for high doses of DDAVP. Other potential endothelial markers, such as fibronectin and thrombospondin, showed no specific increase after any of the stimuli.

Arginine Vasopressin↗
PubMed1980

The heparin-accelerated neutralisation of bovine alpha and beta thrombins by antithrombin III.

The heparin-accelerated neutralisation of bovine alpha and beta thrombins has been examined using a peptide substrate H-D-phenylalanyl-pipecolyl-arginine-paranitroanilide-HCl to measure thrombin amidase activity. Alpha and beta thrombins were both neutralised by antithrombin III and this neutralisation was further accelerated by the presence of small amounts of heparin. Low and high molecular weight heparin and heparins fractionated by their affinity for antithrombin III were all able to accelerate the neutralisation of alpha and beta thrombin. This work is therefore unable to confirm reports that alpha and beta thrombins have different heparin sensitivities.

Animals↗
PubMed1980

The anti-heparin properties of human low-density lipoprotein.

High-density (HDL), low-density (LDL) and very low-density lipoproteins (VLDL) have been purified from normal human plasma by a combination of ultracentrifugation in high-density salt and agarose gel filtration. The ability of these lipoproteins to inhibit different molecular weight heparin fractions has been compared, using incubation mixtures comprised of antithrombin III and factor Xa. Residual factor Xa activity was measured using the chromogenic peptide substrate Bz-Ile-Glu-Gly-Arg-pNA. LDL inhibited the high molecular weight (but not low molecular weight) heparin accelerated neutralisation of factor Xa by antithrombin III. VLDL showed a similar, though much reduced anti-heparin activity, while the addition of HDL to the factor Xa incubation mixture produced no measurable anti-heparin activity. These observations suggest that certain plasma lipoproteins may selectively modulate the inhibitory action of heparin against factor Xa.

Amidohydrolases↗
PubMed1979

Evidence for a plasma inhibitor of the heparin accelerated inhibition of factor Xa by antithrombin III.

The ability of heparin fractions of different molecular weight to potentiate the action of antithrombin III against the coagulation factors thrombin and Xa has been examined in purified reaction mixtures and in plasma. Residual thrombin and Xa have been determined by their peptidase activities against the synthetic peptide substrates H-D-Phe-Pip-Arg-pNA and Bz-Ile-Gly-Arg-pNA. High molecular weight heparin fractions were found to have higher anticoagulant activities than low molecular weight heparin when studied with both thrombin and Xa incubation mixtures in purified mixtures and in plasma. The inhibition of thrombin by heparin fractions and antithrombin III was unaffected by other plasma components. However, normal human plasma contained a component that inhibited the heparin and antithrombin III inhibition of Xa particularly when the high molecular weight heparin fraction was used. Experiments using a purified preparation of platelet factor 4 suggested that the platelet-derived heparin-neutralizing protein was not responsible for the inhibition.

Animals↗
PubMedDate not supplied

Thrombogenicity of a factor IX concentrate quantitated in a canine model.

Dose-ranging studies with a batch of factor IX concentrate have been performed in a canine non-stasis model of thrombogenicity. Doses between 50 and 200 IU/kg were infused over a 30 min period, and beagles were found to be more sensitive than greyhounds with regard to subsequent alterations in haemostatic parameters over a 150 min period. In beagles we detected significant increases in plasma fibrin(ogen) degradation products and reduction in fibrinogen concentrations in a dose-related manner after infusion of factor IX concentrate over the range 50-150 IU/kg. Plasma fibrinopeptide A was the most sensitive marker of activation of coagulation with significantly increased levels after factor IX at 50 IU/kg compared with control infusions of albumin. Recovery of infused factor IX was similar to values reported in man. In these experiments, measurement of urinary fibrinopeptide A did not prove to be a useful indicator of thrombogenicity. In conclusion, the beagle non-stasis model will provide a sensitive method to quantify the unwanted thrombogenic activities associated with the use of high doses of certain factor IX concentrates.

Animals↗
PubMedDate not supplied

Seminal plasma plasminogen activator and fertility.

Seminal plasma samples were tested for plasminogen activation and considerable activity was found. Tests were performed in samples from 42 men with an infertile marriage but no relationship was found between plasminogen activator and fertility. However none of our men had any obvious seminal plasma viscosity or coagulation disorder and further work would involve testing samples from men with these disorders.

Follow-Up Studies↗